Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Type
Public
HQ
Petaluma, US
Size (employees)
38 (est)+12%
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma and Herten
Petaluma, US (HQ)
1129 N Mc Dowell Blvd
Herten, NL
6049 Lx Herten/Roermond

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Data and Metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financial Metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $12.8 m in FY, 2017 which is a 15% decrease from the previous period.
USD

Revenue (FY, 2017)

12.8 m

Revenue growth (FY, 2016 - FY, 2017), %

(15%)

Gross profit (FY, 2017)

5.7 m

Gross profit margin (FY, 2017), %

44%

Net income (FY, 2017)

9.3 m

EBIT (FY, 2017)

(13 m)

Market capitalization (05-Dec-2016)

20.9 m

Closing share price (05-Dec-2016)

4.9

Cash (31-Mar-2017)

17.5 m

EV

3.5 m
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

13.7 m13.9 m15.1 m12.8 m

Revenue growth, %

1%9%(15%)

Cost of goods sold

5.3 m6.6 m7.9 m7.2 m

Gross profit

8.4 m7.3 m7.2 m5.7 m

Gross profit Margin, %

61%53%48%44%

R&D expense

1.6 m

General and administrative expense

17.1 m

Operating expense total

14.4 m13.9 m17.4 m18.6 m

EBIT

(6.1 m)(6.7 m)(10.2 m)(13 m)

EBIT margin, %

(44%)(48%)(67%)(101%)

Interest expense

1.1 m3 k3 k(3 k)

Interest income

1 k1 k2 k22 k

Pre tax profit

(12.9 m)

Income tax expense

4.3 m

Net Income

3.7 m(8.2 m)(10.2 m)9.3 m
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.5 m6.1 m7.5 m17.5 m

Accounts Receivable

1.8 m1.5 m2.3 m2.1 m

Inventories

647 k592 k1.5 m2.2 m

Current Assets

9.5 m9.6 m12.9 m22.6 m

PP&E

971 k795 k850 k1.2 m

Total Assets

20.8 m15 m13.8 m25.5 m

Accounts Payable

736 k932 k1.3 m1.3 m

Total Debt

123 k

Current Liabilities

7.6 m2.6 m3.6 m3.3 m

Total Liabilities

4 m

Additional Paid-in Capital

149.1 m157.8 m166.4 m168.7 m

Retained Earnings

(134 m)(142.2 m)(152.4 m)(143.1 m)

Total Equity

12.1 m12.1 m10.1 m21.4 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.7 x1.2 x1.4 x1.2 x
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.7 m(8.2 m)(10.2 m)9.3 m

Depreciation and Amortization

284 k253 k244 k248 k

Accounts Receivable

(88 k)40 k(1.3 m)34 k

Inventories

(126 k)(627 k)(382 k)(675 k)

Accounts Payable

848 k222 k429 k(58 k)

Cash From Operating Activities

(4.9 m)(6.7 m)(8.7 m)(8.2 m)

Purchases of PP&E

(504 k)(139 k)(345 k)(394 k)

Cash From Investing Activities

(445 k)875 k4.2 m18.2 m

Long-term Borrowings

(1.6 m)(176 k)(119 k)(130 k)

Cash From Financing Activities

2.9 m6.6 m6 m(32 k)

Interest Paid

195 k3 k3 k3 k
USDY, 2017

EV/EBIT

-0.3 x

EV/CFO

-0.4 x

Revenue/Employee

337.5 k

Financial Leverage

1.2 x

Market Position of Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Company Life and Culture

You may also be interested in